Medtronic Launches Innovative MiniMed Go Smart MDI System in Europe

Medtronic's Groundbreaking MiniMed Go™ Smart MDI System Launches in Europe

Medtronic, a leader in healthcare technology, has recently announced the commercial launch of its MiniMed Go™ Smart MDI (multiple daily injection) system in Europe, alongside the Simplera™ sensor. This pioneering system is designed to transform diabetes management for individuals who rely on daily insulin injections. By integrating the smart InPen™ insulin pen with the Simplera sensor, Medtronic presents a holistic mobile app solution for better diabetes care.

A Revolutionary Diabetes Management Tool

The MiniMed Go™ system sets itself apart from conventional connected insulin pens by offering real-time personalized insights and actionable alerts through one user-friendly mobile application. This aims to make diabetes management simpler and more effective for users who administer multiple daily injections. With cutting-edge features like an advanced dose calculator and a built-in reminder system, users can confidently manage their diabetes without the burden of manual tracking.

Research indicates that missing insulin doses can significantly affect glycemic control. Studies have shown that skipping just a couple of doses weekly may lead to an increase in HbA1c levels, raising the risk of complications both in the short and long term. The MiniMed Go™ system seeks to alleviate these issues by offering alerts for missed doses, strengthening the connection between notifications and effective diabetes management.

Improving Clinical Outcomes

Que Dallara, the Executive Vice President and President of Medtronic Diabetes, emphasized the importance of "real-time actionable alerts." According to Dallara, such innovations can lead to better clinical outcomes for individuals managing their diabetes with multiple daily injections. The MiniMed Go™ system remembers, reminds, and recommends the precise dose at opportune moments, alleviating the mental load from users.

Additionally, the MiniMed Go™ system enhances communication between healthcare professionals and patients. The new CareLink Clinic MDI reports allow clinicians to interpret user data more easily, leading to evidence-based decisions and improved conversations with patients about their diabetes management.

Expanding Accessibility Across Europe

The MiniMed Go™ system has been approved to support individuals aged 7 years and older with insulin-requiring diabetes across Europe. For children between the ages of 2 and 6, adult supervision is required when using the system. Furthermore, the integration of the Instinct Go™ sensor, which has been developed by Abbott, is currently pending approval and will give users the option between a 7-day or 15-day sensor based on their needs.

FAQs About the MiniMed Go™ System

Q: What features make the MiniMed Go™ system unique?
A: The MiniMed Go™ system uniquely integrates the InPen™ smart insulin pen with the Simplera sensor, providing real-time glucose insights, dose calculations, missed dose alerts, and actionable guidance through a mobile app, making MDI therapy more dynamic.

Q: What is the InPen™?
A: The InPen™ is an advanced reusable insulin pen equipped with Bluetooth® technology, allowing it to send dosage data directly to the user's mobile app, thereby simplifying diabetes management.

Q: How does the MiniMed Go™ system differ from traditional insulin pens?
A: Unlike traditional pens, the MiniMed Go™ system offers a comprehensive smart solution, tracking doses with real-time updates and providing decision support while facilitating patient adherence to their diabetes therapy.

Medtronic's Commitment to Diabetes Management

For over four decades, Medtronic has been dedicated to improving the lives of people with diabetes. The introduction of the MiniMed Go™ Smart MDI system reflects their ongoing commitment to innovation and patient-centric solutions. By leveraging advanced technology, Medtronic aims to empower individuals to take control of their diabetes with confidence and ease.

As Medtronic rolls out this new system across Europe, many in the healthcare community have welcomed this innovation as a milestone in diabetes care. With ongoing technological advancements, the company strives to establish a more predictable future for diabetes management, bringing hope and support to millions worldwide.